ChromaDex (NASDAQ:CDXC) Earns Buy Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of ChromaDex (NASDAQ:CDXC) in a report issued on Sunday morning. The firm issued a buy rating on the stock.

Several other equities research analysts have also recently weighed in on the stock. LADENBURG THALM/SH SH increased their target price on shares of ChromaDex from $6.80 to $8.10 and gave the company a “buy” rating in a research note on Wednesday, March 5th. HC Wainwright reiterated a “buy” rating and issued a $11.00 price objective on shares of ChromaDex in a research report on Monday, March 17th.

ChromaDex Price Performance

The company has a market capitalization of $611.50 million, a price-to-earnings ratio of 787.29 and a beta of 2.21. ChromaDex has a 52-week low of $2.31 and a 52-week high of $9.18. The business’s 50-day moving average is $6.16 and its two-hundred day moving average is $5.44.

Institutional Trading of ChromaDex

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CDXC. Geode Capital Management LLC boosted its holdings in ChromaDex by 0.5% during the fourth quarter. Geode Capital Management LLC now owns 1,154,778 shares of the company’s stock valued at $6,128,000 after purchasing an additional 5,186 shares in the last quarter. D. E. Shaw & Co. Inc. boosted its stake in ChromaDex by 1,785.9% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 1,011,290 shares of the company’s stock valued at $5,365,000 after buying an additional 957,665 shares in the last quarter. Renaissance Technologies LLC boosted its stake in ChromaDex by 68.0% in the 4th quarter. Renaissance Technologies LLC now owns 712,788 shares of the company’s stock valued at $3,781,000 after buying an additional 288,588 shares in the last quarter. Arrowstreet Capital Limited Partnership grew its position in ChromaDex by 288.1% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 662,956 shares of the company’s stock valued at $3,517,000 after acquiring an additional 492,148 shares during the period. Finally, State Street Corp raised its stake in ChromaDex by 11.3% during the third quarter. State Street Corp now owns 618,028 shares of the company’s stock worth $2,256,000 after acquiring an additional 62,692 shares in the last quarter. Institutional investors own 15.41% of the company’s stock.

About ChromaDex

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.